Artisan Partners Limited Partnership Purchases Shares of 421,201 Bruker Corporation $BRKR

Artisan Partners Limited Partnership acquired a new position in Bruker Corporation (NASDAQ:BRKR) during the third quarter, HoldingsChannel.com reports. The fund acquired 421,201 shares of the medical research company’s stock, valued at approximately $13,685,000.

Several other large investors have also recently modified their holdings of BRKR. Nisa Investment Advisors LLC lifted its position in Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 487 shares during the last quarter. Huntington National Bank increased its position in shares of Bruker by 750.0% during the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after purchasing an additional 645 shares in the last quarter. Spire Wealth Management purchased a new stake in shares of Bruker during the 2nd quarter valued at $32,000. True Wealth Design LLC boosted its position in shares of Bruker by 16,716.7% in the 2nd quarter. True Wealth Design LLC now owns 1,009 shares of the medical research company’s stock worth $42,000 after purchasing an additional 1,003 shares in the last quarter. Finally, Hantz Financial Services Inc. grew its stake in Bruker by 39.5% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,560 shares of the medical research company’s stock worth $64,000 after buying an additional 442 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Insiders Place Their Bets

In other news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $49.20, for a total value of $98,400.00. Following the sale, the vice president owned 128,443 shares in the company, valued at $6,319,395.60. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 27.30% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on BRKR shares. Wolfe Research upgraded Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price target for the company in a research note on Wednesday, December 10th. Zacks Research upgraded Bruker from a “strong sell” rating to a “hold” rating in a research note on Monday, December 8th. Citigroup cut their price objective on shares of Bruker from $53.00 to $40.00 and set a “neutral” rating on the stock in a report on Friday, February 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research note on Monday, December 29th. Finally, Bank of America boosted their target price on shares of Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $50.38.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $40.11 on Friday. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $56.22. The business’s 50 day moving average price is $45.64 and its 200 day moving average price is $40.85. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75. The firm has a market cap of $6.09 billion, a P/E ratio of -267.40, a P/E/G ratio of 2.40 and a beta of 1.19.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The business had revenue of $977.20 million for the quarter, compared to analysts’ expectations of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The business’s quarterly revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts expect that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Monday, March 23rd. Bruker’s dividend payout ratio is presently -133.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.